L
Linus Ho
Researcher at University of Texas MD Anderson Cancer Center
Publications - 57
Citations - 3722
Linus Ho is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chemoradiotherapy & Survival rate. The author has an hindex of 27, co-authored 57 publications receiving 3411 citations.
Papers
More filters
Journal ArticleDOI
Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
Douglas B. Evans,Gauri R. Varadhachary,Christopher H. Crane,Charlotte C. Sun,Jeffrey E. Lee,Peter W.T. Pisters,Jean Nicolas Vauthey,Huamin Wang,Karen R. Cleary,Gregg A Staerkel,Chusilp Charnsangavej,Elizabeth A. Lano,Linus Ho,Renato Lenzi,James L. Abbruzzese,Robert A. Wolff +15 more
TL;DR: The encouraging overall survival observed in this large trial supports the continued investigation of gemcitabine-based preoperative therapy in resectable pancreatic cancer.
Journal ArticleDOI
Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
Gauri R. Varadhachary,Robert A. Wolff,Christopher H. Crane,Charlotte C. Sun,Jeffrey E. Lee,Peter W.T. Pisters,Jean Nicolas Vauthey,Eddie K. Abdalla,Huamin Wang,Gregg A Staerkel,Jeffrey H. Lee,William A. Ross,Eric P. Tamm,Priya Bhosale,Sunil Krishnan,Prajnan Das,Linus Ho,Henry Xiong,James L. Abbruzzese,Douglas B. Evans +19 more
TL;DR: Preoperative Gem-Cis-XRT did not improve survival beyond that achieved with preoperative gemcitabine-based chemoradiation (Gem- XRT) alone, and the Gem-X RT platform is a reasonable foundation on which to build future phase II multimodality trials for stage I/II pancreatic cancer incorporating emerging systemic therapies.
Journal ArticleDOI
Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer.
TL;DR: The EUS with FNA can be a valuable adjunct to newer high-resolution multidetector spiral CT for diagnostic evaluation of patients with suspected pancreatic cancer.
Journal ArticleDOI
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
Christopher H. Crane,Lee M. Ellis,James L. Abbruzzese,Christina Amos,Henry Q. Xiong,Linus Ho,Douglas B. Evans,Eric P. Tamm,Chaan Ng,Peter W.T. Pisters,Chusilp Charnsangavej,Marc E. Delclos,Michael S. O'Reilly,Jeffrey E. Lee,Robert A. Wolff +14 more
TL;DR: Conurrent bevacizumab did not significantly increase the acute toxicity of a relatively well-tolerated chemoradiotherapy regimen, however, ulceration and bleeding in the radiation field possibly related to bevazquezumab occurred when tumor involved the duodenal mucosa.
Journal ArticleDOI
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Jaffer A. Ajani,R N Jackie Baker,Peter W. T. Pisters,Linus Ho,Paul F. Mansfield,Barry W. Feig,Chusilp Charnsangavej +6 more
TL;DR: This Phase II study assessed the response rate and toxicity profile of the combination CPT‐11 and cisplatin administered weekly to patients with untreated, advanced adenocarcinoma of the stomach or the gastroesophageal junction.